News

Eris Lifesciences Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, its Registrar and Share Transfer Agent.

Eris Lifesciences Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the public declaration of the company’s unaudited financial results for the quarter and half year ending September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Eris Lifesciences Limited announced the allotment of 1,55,264 equity shares on September 22, 2026, following the exercise of options under the ESOP-2021 Scheme, with 66,422 shares issued at Rs 557.24, 57,239 shares at Rs 510.32, and 31,603 shares at Rs 728.16, increasing the company`s paid-up share capital from Rs 13,85,83,305 to Rs 13,87,38,569.

Eris Lifesciences Limited announced that Krishnakumar Vaidyanathan has resigned from his position as Executive Director & Chief Operating Officer (COO), effective September 30, 2026, to pursue professional opportunities outside the organization.

Eris Lifesciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its board of directors approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director for a period of 5 years, commencing July 25, 2027, and up to July 24, 2032, and convened the 20th Annual General Meeting of its members for September 25, 2026.